Shapiro CDRBH, et al. - In 2012, researchers reported on the prevalence of hepatitis C virus (HCV) infection in Veterans Affairs (VA) patients undergoing total joint arthroplasty (TJA) at their center. In this study, they provided updated information on HCV viremia prevalence among patients undergoing primary TJA via performing a retrospective review of all patients undergoing primary TJA in 2019 at the same VA medical center. Positive results for the hepatitis C antibody were reported in 33 (11.6%) of 285 patients screened preoperatively. At the time of screening, only one of the 33 anti-HCV–positive patients was viremic for an overall viremic prevalence of 0.4%. Observations revealed that among VA patients undergoing TJA, HCV viremia has reduced from 4.5% to 0.4% as direct-acting antiviral HCV treatment has become available. Surgeons are still advised to reduce the risk of sharps injury.